Who
Aleksandra Rizo
Director
Company insider
Files Form 4 as: Director, Syndax Pharmaceuticals; EVP, Chief Medical Officer, Geron.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 30 Jan 2019
- Last trade
- 4 Feb 2026
- Last filed
- 6 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 May 2024filed 16 May 2024 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 16 Feb 2022filed 18 Feb 2022 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 2 Feb 2021filed 4 Feb 2021 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 12 Feb 2020filed 14 Feb 2020 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —291,375 at $0.00 | filing |
| 30 Jan 2019filed 1 Feb 2019 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.